Multidrug Resistance-Associated Protein 1 Predicts Relapse in Iranian Childhood Acute Lymphoblastic Leukemia

  • Mahjoubi, Frouzandeh (Clinical Genetic Dept, National Institute of Genetic Engineering and Biotechnology (NIGEB)) ;
  • Akbari, Soodeh (Clinical Genetic Dept, National Institute of Genetic Engineering and Biotechnology (NIGEB))
  • Published : 2012.05.30


Multidrug resistance (MDR) is a main cause of failure in the chemotherapeutic treatment of malignant disorders. One of the well-known genes responsible for drug resistance encodes the multidrug resistance-associated protein (MRP1). The association of MRP1 with clinical drug resistance has not systematically been investigated in Iranian pediatric leukemia patients. We therefore applied real-time RT-PCR technology to study the association between the MRP1 gene and MDR phenotype in Iranian pediatric leukemia patients. We found that overexpression of MRP1 occurred in most Iranian pediatric leukemia patients at relapse. However, no relation between MRP1 mRNA levels and other clinical characteristics, including cytogenetic subgroups and FAB subtypes, was found.


MDR;multidrug resistance-associated protein (MRP1) gene;leukemia;Real-time RT-PCR


  1. Ambudkar SV, Dey S, Hrycyna CA, et al (1999). Biochemical, cellular and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol, 39, 361-98.
  2. Borst P, Evers R, Kool M, Wijnholds JJ (2000). Title??? J Natl Cancer Inst, 92, 1295-302.
  3. Bunting KD (2002). ABC transporters as phenotypic markers and functional regulators of stem cells. Stem Cells, 20, 11-20.
  4. Cole SPC, Bhardwaj G, Gerlach JH, et al (1992). Overexpression of a novel transporter gene in a multidrug resistant human lung cancer cell line. Science, 258, 1650.
  5. Cole SP, Bhardwaj G, Gerlach JH, et al (1992). Science, 258, 1650-4.
  6. Endicott JA, Ling V (1989).Title??? Annu Rev Biochem, 58, 137-71.
  7. Fardel O Lecureur V, Guillouzo A (1996). The P-glycoprotein multidrug transporter. Gen Pharmacol, 27, 1283-91.
  8. Gottesman MM, Fojo T, Bates SE (2002). Multidrug resistance in cancer, role of ATP-dependent transporters. Nat Rev Cancer, 2, 48-58.
  9. Gottesman MM, Hrycyna CA, Schoenlein PV (1995). Genetic analysis of the multidrug transport. Annu Rev Genel, 29, 607-49.
  10. Gottesman MM, Licht T, Zhou Y, et al (2000). Selectable markers for gene therapy. In Gene Therapy: Therapeutic Mechanisms and Strategies, ed. D Lasic, N Templeton, 16, 333-52.
  11. Gottesman MM, Pastan I (1993). Title??? Annu Rev Biochem, 62, 385-427.
  12. Gottesman MM, Fojo T, Bates SE (2002).Title??? Nat Rev Cancer, 2, 48-58.
  13. Higgins CF (1992).Title??? Ann Rev Cell Biol, 8, 67-113.
  14. Hipfner DR, Deeley RG, Cole SP (1999). Structural, mechanistic and clinical aspects of MRP1. Biochim Biophys Acta, 1461, 359-76.
  15. Holleman A, Cheok MH, Den Boer ML, et al (2004). Gene expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N Engl J Med, 351, 533-42.
  16. Jean-Pierre Marie, Olliver LeGrand (2003). Drug resistance in acute leukaemia and reversion. Turk J Med Sci, 33, 271-9.
  17. Klein I, Sarkadi B, Varadi A (1999). Biochim Biophys Acta, 1461, 237-62.
  18. Kool M, De Haas M, Scheffer GL, et al (1997). Analysis of expression of cMOAT (MRP2), MRP3, MRP4 and MRP5, homologs of the multidrug resistance-associated protein gene (MRP1), in human cancer cell line. Cancer Res, 57, 3537.
  19. Kool M, Van Der Linden M, De Haas M, Baas F, Borst P (1999). Expression of human MRP6, a homologue of the multidrug resistance protein gene MRP1, in tissues and cancer cells. Cancer Res, 59, 175.
  20. Krishna R, Mayer LD (2000). Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur J Pharm Sci, 11, 265-83.
  21. Leslie EM, Deeley RG, Cole SP (2001). Toxicological relevance of the multidrug resistance protein 1, MRP1 (ABCC1) and related transporters. Toxicology, 167, 3-23.
  22. Mitelman F (1991 ). ISCN Guidelines for Cancer Cytogenetics: Supplement to an International System for Human Cytogenetic Nomenclature. Basel, Switzerland, Karger.
  23. Plasschaert SL, Vellenga E, De Bont ES, et al (2003). High functional P-glycoprotein activity is more often present in T-cell acute lymphoblastic leukaemic cells in adults than in children. Leuk Lymphoma, 44, 85-95.
  24. Ros JE, Libbrecht L, Geuken M, Jansen PL, Roskams TA (2003). High expression of MDR1, MRP1and MRP3 in the hepatic progenitor cell compartment and hepatocytes in several human liver disease. J Pathol, 200, 553-60.
  25. Sabine L, Plasschaert A, Eveline SJM (2005). Expression of multidrug resistance-associated proteins predicts prognosis in childhood and adult acute lymphoblastic leukemia. Clin Cancer Res, 11, 24.
  26. Sauerbrey A, Voigt A, Writtig S, Hafer R, Zintl F (2002). Messenger RNA analysis of the multidrug resistance related protein (MRP1) and the lung resistance protein (LRP) in de novo and relapsed childhood acute lymphoblastic leukemia. Leuk Lymphoma, 43, 875-9.
  27. Simon M, Schindler M (1994). Cell biological mechanisms of multidrug resistance in tumors. Proc Natl Acad Sci USA, 91, 3497.
  28. Sonneveid P (2000). Multidrug resistance in haematological malignancies. J Intern Med, 247, 521-34.
  29. Strautnieks SS, Bull LN, Knisely AS (1998). Nat Genet, 20, 233-8.
  30. Taniguchi K, Wada M, Kohno K, et al (1996). A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin-resistant human cancer cell lines with decreased drug accumulation. Cancer Res, 56, 4124.
  31. Thomas R (2000). Chemotherapy resistance in acute leukemia. Turk J Haematol, 17, 155-162.
  32. Ueda K, Taguchi Y, Morishima M (1997).Title??? Semin Cancer Biol, 8, 151-9.
  33. Wijnholds J, Mol CA,Van Deemter L, et al (2000). Multidrug-resistance protein 5 is a multispecific organic an-ion transporter able to transport nucleotide analogs. Proc Natl Acad Sci USA, 97, 7476-81.
  34. Wijnholds J, Mol CA, Van Deemter L, et al (2003). Multidrugresistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs. Proc Natl Acad Sci USA, 97, 7476-81.
  35. Yoshida M, Suzuki T, Komiva T, et al (2001). Induction of MRP5 and SMRP mRNA by Adriamycin exposure and its overexpression in human lung cancer cells resistant to Adriamycin. Int J Cancer, 94, 432-7.

Cited by

  1. Reversal of Resistance towards Cisplatin by Curcumin in Cervical Cancer Cells vol.15, pp.3, 2014,
  2. RNAi-based Knockdown of Multidrug Resistance-associated Protein 1 is Sufficient to Reverse Multidrug Resistance of Human Lung Cells vol.15, pp.24, 2015,
  3. High Expression of Lung Resistance Protein mRNA at Diagnosis Predicts Poor Early Response to Induction Chemotherapy in Childhood Acute Lymphoblastic Leukemia vol.16, pp.15, 2015,
  4. MRP1 and its role in anticancer drug resistance vol.47, pp.4, 2015,